Amphilix AG

Amphilix is developing a first-in-class radioligand therapy targeting GPR4, a novel receptor overexpressed in colorectal cancer and multiple solid tumors with low background expression comparable to PSMA and SSTR2. By moving beyond crowded RLT targets, Amphilix addresses large underserved oncology markets. Its proprietary small-molecule, 3D-linker platform enables deep tumor penetration, long tumor residence, and minimal kidney uptake versus peptide-based agents. Lead candidates AMX-0053 and AMX-0059 show high, selective tumor uptake in vivo and are ready to be advanced into First-in-Human imaging. The project is,supported by an Innosuisse funded strategic collaboration with the Paul Scherrer Institute (PSI) and ETH Zürich.